Diabetes cell therapies take evasive action
Elie Dolgin • February 25, 2022
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Continue reading at Nature Biotechnology.
Fresh treatments shift the focus from symptom management to repair.
Smart algorithms take aim at antimicrobial resistance.